Artis BioSolutions Appoints Dr. Kate Broderick as Chief Scientific Innovation Officer

San Diego, CA – Artis BioSolutions has appointed Dr. Kate Broderick, Ph.D., as its new Chief Scientific Innovation Officer, effective February 9, 2026. This strategic move aims to strengthen the company’s scientific leadership and accelerate its advancements in synthetic DNA strategy, particularly as it prepares for the acquisition of Syngoi Technologies.

Dr. Broderick’s Background and Expertise

Prior to joining Artis BioSolutions, Dr. Broderick served as Senior Vice President of Research and Development at Inovio Pharmaceuticals. Her extensive experience in the field positions her to drive innovation in nucleic acid medicines and oversee the development and manufacturing of advanced therapies.

About Artis BioSolutions

Artis BioSolutions is a San Diego-based platform company focused on developing and manufacturing advanced therapies. The company is dedicated to building and scaling differentiated capabilities to support the entire lifecycle of advanced therapeutic programs. Artis BioSolutions collaborates with biotech and pharmaceutical companies, providing integrated solutions and expanding its global presence, including Landmark Bio in Boston.

Strategic Expansion and Future Outlook

The appointment of Dr. Broderick, alongside the pending acquisition of Syngoi Technologies, underscores Artis BioSolutions’ commitment to synthetic DNA strategy and its vision of creating a comprehensive ecosystem for next-generation genetic medicines. This expansion of leadership and scientific capabilities is expected to accelerate innovation within the company.

Connect with Dr. Kate Broderick

You can uncover Dr. Kate Broderick on LinkedIn.